<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863703</url>
  </required_header>
  <id_info>
    <org_study_id>9644_BO_S_2021</org_study_id>
    <nct_id>NCT04863703</nct_id>
  </id_info>
  <brief_title>Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)</brief_title>
  <acronym>IMPHROVE-D</acronym>
  <official_title>Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with&#xD;
      liver cirrhosis. It has been demonstrated that antiviral therapy in patients with chronic&#xD;
      hepatitis C infection leads to a decrease of PH and is associated with an improved outcome.&#xD;
      Recently, Bulevirtide was approved for the treatment of patients coinfected with hepatitis B&#xD;
      (HBV) and chronic hepatitis delta (HDV) infection, which helps to achieve viral supression in&#xD;
      these patients. This study investigates the potential effects of viral supression on PH in&#xD;
      patients with chronic HBV/HDV infection and liver cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change the degree of portal hypertension after inducing viral suppression via antiviral treatment with Bulevirtide</measure>
    <time_frame>Measurement before antiviral treatment (baseline) and one year after inducing viral suppression with Bulevirtide.</time_frame>
    <description>Change of hepatovenous pressure gradient (HVPG) in mmHg underviral suppression with Bulevirtide in patients with HBV/HDV coinfection and liver cirrhosis. HVPG measurement will be assessed via transjugular HVPG measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Quality of life under viral suppression with Bulevirtide</measure>
    <time_frame>Measurement before Bulevirtide intake (baseline) and one year after establishing antiviral treatment.</time_frame>
    <description>Change of Quality of life is assessed via SF-36 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in minimal hepatic encephalopathy (HE) status under viral suppression</measure>
    <time_frame>Measurement before antiviral treatment (baseline) and one year after inducing viral suppression with Bulevirtide.</time_frame>
    <description>Change in minimal HE status is evaluated via PSE-testing, critical flicker frequency and animal naming test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of nutritional status under viral suppression with Bulevirtide</measure>
    <time_frame>Measurement before antiviral treatment (baseline) and one year after inducing viral suppression with Bulevirtide.</time_frame>
    <description>Change of nutritional status will be evaluated via repeated measurement of BMI (in kg/m2), arm circumference and triceps skin fold thickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of physical ability under viral suppression with Bulevirtide</measure>
    <time_frame>Measurement before antiviral treatment (baseline) and one year after inducing viral suppression with Bulevirtide.</time_frame>
    <description>Change of physical ability is assessed via liver-frailty Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the inflammatory profile under viral suppression with Bulevirtide</measure>
    <time_frame>Measurement before antiviral treatment (baseline) and one year after inducing viral suppression with Bulevirtide.</time_frame>
    <description>Change of the inflammatory profile will be assessed through Cytokines using Bio-Plex Pro Human Cytokine Screening Panel, 48-Plex, Bio-Rad, Olink Target 96 Inflammation and Olink Proteomics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver stiffness under viral suppression with Bulevirtide</measure>
    <time_frame>Measurement before Bulevirtide intake (baseline) and one year after establishing antiviral treatment with Bulevirtide.</time_frame>
    <description>Change in liver stiffness will be assessed via transient elastography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical endpoints under viral suppression with Bulevirtide</measure>
    <time_frame>Measurement before antiviral treatment (baseline) and one year after inducing viral suppression with Bulevirtide.</time_frame>
    <description>Assessed clinical endpoints are: Resolution of esophageal varices and incidence of esophageal bleeding, hepatic encephalopathy or ascites.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Hepatitis D</condition>
  <condition>Hepatitis B</condition>
  <condition>Portal Hypertension</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>One group with HBV/HDV coinfection</arm_group_label>
    <description>Measurement of HVPG before antiviral treatment of HBV/HDV coinfection and one year after treatment initiation with Bulevirtide. Administration of Bulevirtide and HVPG measurement is independent from this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bulevirtide</intervention_name>
    <description>Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.</description>
    <arm_group_label>One group with HBV/HDV coinfection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study populations consists out of patients with HBV/HDV coinfection, diagnosed or&#xD;
        suspected liver cirrhosis. All patients must have a medical indication for HVPG measurement&#xD;
        or had a HVPG measurement within the last 12 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic HBV/HDV Coinfection&#xD;
&#xD;
          -  suspected or diagnosed liver cirrhosis, indication for hepatovenous pressure gradient&#xD;
             (HVPG) measurement or liver cirrhosis and HVPG measurement conducted in the past 12&#xD;
             months (conducted prior to antiviral treatment)&#xD;
&#xD;
          -  indication for antiviral treatment with Bulevirtide&#xD;
&#xD;
          -  age &gt;18years&#xD;
&#xD;
          -  Must be willing to participate in the study and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient rejects study participation&#xD;
&#xD;
          -  no conducted or no indication for HVPG measurement&#xD;
&#xD;
          -  age &lt;18years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Maasoumy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Maasoumy, MD</last_name>
    <phone>+49511 532 6529</phone>
    <email>Maasoumy.Benjamin@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tammo L Tergast, MD</last_name>
    <email>tergast.tammo@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Maasoumy, MD</last_name>
      <phone>+495115326529</phone>
      <email>Maasoumy.Benjamin@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Tammo L Tergast, MD</last_name>
      <email>tergast.tammo@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Maasoumy, Benjamin PD Dr</investigator_full_name>
    <investigator_title>PD Dr. med. Benjamin Maasoumy</investigator_title>
  </responsible_party>
  <keyword>Portal hypertension, Liver cirrhosis, Bulevirtide, Hepatitis D, Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

